首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL19 |
| Uniprot No | Q9UHD0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-177aa |
| 氨基酸序列 | MLRRCLISTD MHHIEESFQE IKRAIQAKDT FPNVTILSTL ETLQIIKPLD VCCVTKNLLA FYVDRVFKDH QEPNPKILRK ISSIANSFLY MQKTLRQCQE QRQCHCRQEA TNATRVIHDN YDQLEVHAAA IKSLGELDVF LAWINKNHEV MFSA |
| 预测分子量 | 20 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL-19重组蛋白的虚构参考文献示例(仅供格式参考，非真实文献)：
---
1. **文献名称**: *Recombinant IL-19 Promotes Anti-inflammatory Macrophage Polarization in Vitro*
**作者**: Zhang Y, et al.
**摘要**: 研究通过大肠杆菌表达系统制备重组IL-19蛋白，并验证其在体外诱导巨噬细胞向M2表型极化的能力，表明IL-19可能通过调节STAT3通路抑制促炎因子释放。
2. **文献名称**: *IL-19 Modulates Airway Inflammation in a Murine Asthma Model*
**作者**: Smith JL, et al.
**摘要**: 利用重组小鼠IL-19蛋白处理哮喘模型，发现其通过抑制Th17细胞分化减轻气道高反应性，提示IL-19在过敏性炎症中的潜在治疗作用。
3. **文献名称**: *Expression and Functional Characterization of Human IL-19 in Mammalian Cell Systems*
**作者**: Kim H, Park S.
**摘要**: 在HEK293细胞中重组表达人源IL-19.证实其通过IL-20Rβ受体激活下游JAK-STAT信号通路，并促进角质形成细胞的迁移与修复。
4. **文献名称**: *The Role of IL-19 in Diabetic Wound Healing: A Recombinant Protein-Based Study*
**作者**: Gupta R, et al.
**摘要**: 局部应用重组IL-19蛋白显著加速糖尿病小鼠皮肤伤口愈合，机制涉及血管生成增强及TGF-β1表达上调。
---
**注意**：以上文献为示例，实际研究中请通过PubMed、Google Scholar等平台检索真实文献(关键词如"IL-19 recombinant protein"或"IL-19 in inflammation")。
Interleukin-19 (IL-19), a member of the IL-10 cytokine family, is a pleiotropic cytokine primarily implicated in immunoregulatory and inflammatory processes. Discovered in 2000. it shares structural homology with IL-10 but exhibits distinct receptor-binding properties, signaling through a heterodimeric receptor complex (IL-20R1/IL-20R2) also utilized by IL-20 and IL-24. IL-19 is predominantly produced by immune cells, including monocytes, macrophages, and B-cells, as well as epithelial and endothelial cells under inflammatory conditions. Its expression is upregulated in autoimmune diseases, chronic inflammation, and certain cancers, suggesting context-dependent roles in pathogenesis.
Recombinant IL-19 protein is generated via genetic engineering, typically using mammalian expression systems (e.g., HEK293 cells) to ensure proper post-translational modifications. This engineered protein retains bioactivity for in vitro and in vivo studies, enabling researchers to investigate IL-19's dual role in immunity. While IL-19 has been associated with promoting Th2-type responses and tissue repair, it also exacerbates diseases like psoriasis, rheumatoid arthritis, and atherosclerosis by stimulating pro-inflammatory cytokines (e.g., IL-6. TNF-α). Such contradictory effects highlight its complex interplay with cellular microenvironments.
Current research focuses on clarifying IL-19's signaling pathways, particularly its cross-talk with STAT3 and NF-κB, and its regulatory effects on angiogenesis and cell survival. Recombinant IL-19 serves as a critical tool for drug screening, mechanistic studies, and therapeutic exploration. Emerging evidence suggests its potential as a biomarker or therapeutic target, though clinical applications require further validation. Challenges remain in reconciling its pro- and anti-inflammatory functions across different disease models, underscoring the need for context-specific investigations.
×
